Makes prosthetic limbs, orthotic braces and compression products for mobility and rehabilitation.
Makes prosthetic limbs, orthotic braces and compression products for mobility and rehabilitation.
Sells products to prosthetists and orthotists and increasingly owns clinics that fit and service them, so it earns both the product and the patient-care margin. Insurers and healthcare systems pay for the devices, so reimbursement policy matters. Formerly Össur, it was renamed Embla Medical in 2023.
Moat: narrow (brand, IP / patents, distribution). Long-standing brand and clinical relationships with prosthetists, plus patented bionic/microprocessor technology.
Headquarters: Reykjavik, Iceland · Founded: 1971 · Employees: 4,192
Size Embla Medical hf (EMBLA.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $1.72B, the 36th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 27.35 on 18 Nov 2026.
Performance Over six months the shares gained 1.5%, against +3.5% for the median peer and +6.3% for the Denmark market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +10.9%); the operating margin is 13.6% (peer median 12.7%).
Valuation It trades at 17.2× forward earnings against a peer median of 27.0× (5th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 6.41B | DKK 6.14B | DKK 5.89B | DKK 5.41B | DKK 5.09B |
| Revenue growth | — | +4% | +9% | +6% | — |
| Gross profit | DKK 3.72B | DKK 3.57B | DKK 3.45B | DKK 3.13B | DKK 2.89B |
| EBITDA | DKK 1.28B | DKK 1.23B | DKK 1.16B | DKK 947M | DKK 952M |
| Net income | DKK 607M | DKK 551M | DKK 471M | DKK 402M | DKK 301M |
| Free cash flow | DKK 764M | DKK 758M | DKK 632M | DKK 449M | DKK 313M |
| Capital expenditure | DKK 165M | DKK 214M | DKK 270M | DKK 291M | DKK 184M |
| Total debt | DKK 3.23B | DKK 3.44B | DKK 3.60B | DKK 3.16B | DKK 3.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Embla Medical hf EMBLA.CO | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% |
| Ottobock SE & Co. KGaA OBCK.DE | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMBLA.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.0% | -5.0% | 7th highest of 21 |
| 6-month return | +1.5% | +3.5% | 10th lowest of 20 |
| Distance from 52-week high | -27.8% | -23.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +6.0% | +10.9% | 7th lowest of 21 |
| Operating margin | 13.6% | 12.7% | 10th highest of 21 |
| Forward P/E | 17.2× | 27.0× | 5th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -1.9% | 13.8% | 2nd least demanding of 14 |
| Growth delivered (Del g) | +8.3% | +12.9% | 5th lowest of 14 |
| Hurdle (Req g minus delivered) | -10.3 pp | -0.3 pp | 5th least demanding of 14 |
| ROIC minus cost of capital | +2.6 pp | -0.6 pp | 9th highest of 21 |
| EV / EBITDA | 11.2× | 16.8× | 6th cheapest of 15 |
| Net debt / EBITDA | 2.1× | -0.8× | 4th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |